Form 4: Natera Insider Sells Shares Under 10b5-1 Plan
Statement of Changes in Beneficial Ownership
Natera Inc. reports insider Solomon Moshkevich sold 2,900 shares of common stock on July 1, 2026, as part of a pre-arranged trading plan.
Summary
- Solomon Moshkevich, President of Clinical Diagnostics at Natera, Inc., executed a sale of 2,900 shares of common stock on July 1, 2026.
- The transactions were conducted under a Rule 10b5-1 trading plan, adopted on November 26, 2024, which is designed to comply with affirmative defense conditions.
- The sales resulted in a decrease of 2,900 shares from Moshkevich's beneficial ownership, leaving him with 134,643 shares.
- The weighted average sale price for the 100 shares was $267.185, and for the 2,600 shares was $272.99.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral filing, as the reported stock sales were executed under a pre-established Rule 10b5-1 trading plan, mitigating concerns about opportunistic insider selling.
Negatives
- Insider selling can sometimes be interpreted negatively by the market, although this sale was conducted under a pre-planned 10b5-1 trading plan.
Risks
- The Rule 10b5-1 trading plan is subject to market conditions and the specific terms of the plan, which are not fully detailed in this filing.
Future Outlook
The filing does not contain forward-looking statements or guidance. It solely reports on past transactions.
Industry Context
StockSavvy.ai notes that insider sales under Rule 10b5-1 plans are common and are intended to provide a defense against accusations of insider trading by establishing a pre-determined plan for stock transactions. The execution of such plans by executives like Natera's President of Clinical Diagnostics is a routine event in public companies.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Rule 10b5-1 Plan Execution | Sale of securities executed under a pre-arranged Rule 10b5-1 trading plan. | 07/01/2026 | Demonstrates adherence to established corporate governance practices for insider stock transactions, providing a defense against insider trading allegations. |
Stakeholder Impact
- Shareholders: The sale, being part of a pre-planned 10b5-1, is unlikely to have a significant negative impact, but any insider selling can be a point of observation.
Next Steps
- Continued adherence to the Rule 10b5-1 trading plan for future transactions, if applicable.
- Monitoring of Natera, Inc.'s stock performance and future SEC filings.
Key Dates
| Date | Description |
|---|---|
| 11/26/2024 | Date the Rule 10b5-1 trading plan was adopted by the Reporting Person. |
| 07/01/2026 | Date of the reported transactions (sale of common stock). |
| 07/06/2026 | Date the Form 4 was signed by the attorney-in-fact. |
Keywords
Natera Inc., NTRA, Form 4, Insider Trading, Rule 10b5-1, Stock Sale, Beneficial Ownership, Solomon Moshkevich, Clinical Diagnostics
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.